证券代码：688363 证券简称：华熙生物 公告编号：2025-003 减持计划的实施结果情况 重要内容提示： 大股东持股的基本情况 本次减持计划实施前，国寿成达（上海）健康产业股权投资中心（有限合伙） （以下简称"国寿成达"）直接持有华熙生物科技股份有限公司（以下简称"本 公司"）股份数量为 34,433,286 股，占本公司总股本的 7.15%。上述股份全部为 本公司首次公开发行前股份，并已于 2022 年 11 月 7 日起上市流通。 截至 2025 年 1 月 28 日，本次减持时间区间已届满，国寿成达在减持期间内 共计减持本公司股份 5,496,782 股，占本公司总股本 1.14%，其中以集中竞价方 式减持 4,816,782 股，占本公司总股本 1.00%，以大宗交易方式减持 680,000 股， 占本公司总股本 0.14%，实际减持数量占计划减持数量的比例为 45.65%。 华熙生物科技股份有限公司股东减持计划时间区 间届满暨减持股份结果公告 本公司于 2024 年 10 月 9 日披露《华熙生物科技股份有限公司股东减持股份 计划公告》（公告编号：2024-034），国寿成达计划根据市场情况通 ...

Investment Rating - The investment rating for the company is "Outperform" (maintained) [1] Core Views - The company is undergoing a transformation period, with expectations that the skincare segment will bottom out in 2025. The management is implementing structural changes and strategic investments to enhance long-term growth potential despite short-term performance pressures [5][7][8]. Financial Data and Profit Forecast - Total revenue for 2023 is projected at 6,076 million, with a year-on-year decline of 4.5%. For 2024, the expected revenue is 5,458 million, reflecting a further decline of 10.2%. However, a recovery is anticipated in 2025 with revenue projected at 5,750 million, representing a growth of 5.3% [6][10]. - The net profit attributable to the parent company for 2023 is estimated at 593 million, with a significant drop to 162 million in 2024, a decrease of 72.7%. A rebound is expected in 2025 with a forecasted profit of 451 million, marking a growth of 179.1% [6][10]. - The company’s gross margin is expected to improve gradually from 73.3% in 2023 to 75.1% by 2026, indicating enhanced operational efficiency [6]. Management Changes and Strategic Investments - The company is committed to management reforms, which include organizational restructuring and a new compensation system, leading to short-term cost increases exceeding 70 million. These changes are aimed at laying a solid foundation for long-term development [5]. - Significant investments exceeding 200 million are being made in supply chain upgrades and innovative business areas such as regenerative medicine and functional foods, which are expected to enhance the company's competitive edge in the long run [5][8]. Market Performance and Comparisons - The company's stock closed at 49.24 yuan on January 24, 2025, with a market capitalization of 23,718 million. The stock has seen a yearly high of 84.59 yuan and a low of 44.72 yuan [1]. - The company’s performance is being compared against the Shanghai Composite Index and the Shenzhen Component Index, with the stock's performance being closely monitored in relation to these benchmarks [1][2].

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Views - The company is expected to achieve a net profit attributable to shareholders of 146 to 175 million yuan in 2024, representing a year-on-year decrease of 70.47% to 75.36% [5] - The functional skincare segment is under pressure, while the medical beauty business is experiencing rapid growth, with expectations for a rebound in functional skincare by the second half of 2025 [6][10] - Strategic investments and organizational changes have led to increased costs, impacting the company's current operating performance [6][11] Summary by Sections Financial Performance - The company forecasts a significant decline in net profit for 2024, with a projected net profit of 163 million yuan, down 72.49% year-on-year [11] - Revenue estimates for 2024 to 2026 have been adjusted to 5.368 billion, 6.146 billion, and 7.3 billion yuan respectively, reflecting downward revisions of 5% to 6% [11] Business Segments - The raw materials business is expected to grow at a high single-digit rate in 2024, benefiting from international expansion and local operations [6] - The medical beauty segment has shown outstanding growth, with new product launches expected to drive revenue in 2025 [7][8] - The functional skincare segment is undergoing a strategic upgrade, with new products aimed at addressing skin issues at the cellular level [10] Market Position and Strategy - The company is positioned as a full-chain platform, integrating raw materials, medical terminal products, functional skincare, and functional foods [11] - The introduction of new medical beauty products is anticipated to significantly contribute to overall revenue growth in 2025 [7][11]

Financial Performance - The company expects a net profit attributable to shareholders of RMB 146 million to RMB 175 million for 2024, a decrease of RMB 417.56 million to RMB 446.56 million, representing a year-on-year decline of 70.47% to 75.36%[2] - The expected net profit attributable to shareholders after deducting non-recurring gains and losses is RMB 80 million to RMB 109 million, a decrease of RMB 381.48 million to RMB 410.48 million, representing a year-on-year decline of 77.78% to 83.69%[2] - The previous year's net profit attributable to shareholders was RMB 592.56 million, with a total profit of RMB 701.72 million[3] - The company has experienced a decrease in government subsidies directly impacting current profits compared to the previous year[9] Business Development - The company has maintained steady growth in its raw material business, benefiting from localized operations in international markets, leading to sustained sales growth in Europe, Japan, and the Americas[5] - The company launched two new medical aesthetic injection products under its brand, which are expected to enhance its product line and market presence[5] - The company has increased strategic investments in emerging business areas such as regenerative medicine and functional foods, with over RMB 100 million allocated to innovation initiatives[6] Management and Strategy - Management transformation initiatives have incurred costs exceeding RMB 70 million, impacting short-term profitability but laying a foundation for long-term growth[5] - The company is undergoing a strategic upgrade focused on high-quality growth and operational efficiency improvements, which may create greater long-term development space despite short-term pressures[8] Impairment and Provisions - A significant impairment provision of approximately RMB 210 million has been made for accounts receivable, inventory, and goodwill due to impairment indications[6]

中国北京建国门外大街 1 号国贸写字楼 2 座 12-15 层 100004 12-14th Floor, China World Office 2, No. 1 Jianguomenwai Avenue, Beijing 100004, China 电话 Tel: +86 10 6563 7181 传真 Fax: +86 10 6569 3838 电邮 Email: beijing@tongshang.com 网址 Web: www.tongshang.com 北京市通商律师事务所 关于华熙生物科技股份有限公司 2024 年第一次临时股东大会的法律意见书 致：华熙生物科技股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》（以下简称"《证券法》"）、《上市公司股东大会规则》 （以下简称"《股东大会规则》"）等法律、法规及规范性文件和《华熙生物 科技股份有限公司章程》（以下简称"《公司章程》"）的规定，北京市通商 律师事务所（以下简称"通商"或"本所"）接受华熙生物科技股份有限公司 （以下简称"公司"）委托，指派本所律师出席了公司于 2024年 12月 2日召开 的 ...

2024 年第一次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688363 证券简称：华熙生物 公告编号：2024-042 华熙生物科技股份有限公司 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2024 年 12 月 02 日 （二） 股东大会召开的地点：北京市朝阳区建国门外大街甲六号华熙国际中心 D 座 36 层会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 390 | | --- | --- | | 普通股股东人数 | 390 | | 2、出席会议的股东所持有的表决权数量 | 329,682,535 | | 普通股股东所持有表决权数量 | 329,682,535 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 68.9189 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | ...

证券代码：688363 证券简称：华熙生物 公告编号：2024-041 华熙生物科技股份有限公司 关于召开 2024 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 董事、副总经理兼董事会秘书：李亦争先生 独立董事：陈关亭先生 投资者可于 2024 年 12 月 02 日(星期一) 至 12 月 06 日(星期五)16:00 前登录上 证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@bloomagebiotech.com 进行提问。公司将在说明会上对投资者普遍关注的问题 进行回答。 华熙生物科技股份有限公司（以下简称"公司"）已于 2024 年 10 月 31 日发 布公司 2024 年第三季度报告，为便于广大投资者更全面深入地了解公司 2024 年第三季度经营成果、财务状况，公司计划于 2024 年 12 月 09 日上午 09:00-10:00 举行 2024 年第 ...

华熙生物科技股份有限公司 2024 年第一次临时股东大会会议资料 证券代码: 688363 证券简称：华熙生物 ะ熙生物科技股份有限公司 BLOOMAGE BIOTECHNOLOGY CORPORATION LIMITED 2024 年第一次临时股东大会会议资料 2024 年 12 月 2024 年第一次临时股东大会会议须知 为保障华熙生物科技股份有限公司（以下简称"公司"）全体股东的合法权益， 维护股东大会的正常秩序，保证股东大会的议事效率，确保本次股东大会如期、 顺利召开，根据《中华人民共和国公司法》《华熙生物科技股份有限公司章程》 《华熙生物科技股份有限公司股东大会议事规则》等相关规定，特制定公司 2024 年第一次临时股东大会会议须知： 一、为保证股东大会的有序进行，切实维护股东的合法权益，现场出席会议的股 东及股东代理人需进行会议登记，以核实股东资格。会议开始后，现场会议登记 将终止，会议主持人将宣布现场出席会议的股东和代理人人数及所持有表决权的 股份总数。为了顺利参加股东大会，建议股东提前半小时到达会议现场，并按规 定出示会议登记所需资料办理会议登记。 二、为保证股东大会的正常秩序，除出席会议的股 ...

Investment Rating - The report maintains a "Buy" rating for the company [6]. Core Views - The company's revenue for Q3 2024 was 1.064 billion yuan, a year-on-year decline of 7.1%, while the net profit attributable to the parent company was 20.26 million yuan, down 77.4% year-on-year. The net profit after deducting non-recurring items was 10.58 million yuan, a decrease of 85.4% year-on-year [4]. - The skincare business is undergoing adjustments, and the launch of new medical beauty products is expected to drive future growth. The revenue changes for the first three quarters of 2024 were 4.2%, -18.1%, and -7.1% year-on-year, with a smaller decline in Q3 compared to Q2. Recent launches include "Injectable Sodium Hyaluronate Composite Solution" and "Injectable Cross-linked Sodium Hyaluronate Gel," which are anticipated to boost future growth [4][5]. - The financial expense ratio continues to improve, but profitability is under temporary pressure. In Q3 2024, the gross profit margin increased by 1.3 percentage points, likely due to a higher proportion of medical terminal business. The net profit margin decreased by 5.9 percentage points to 1.9% year-on-year [5]. - The company is focusing on overall resource efficiency and internal management reforms. The medical beauty business is on a positive development track, and the new products are expected to enhance revenue and profit. The raw material business has a solid market position and broad potential, while the contribution of the medical beauty business is gradually increasing [5]. Summary by Sections Revenue Performance - In Q3 2024, the company achieved revenue of 1.064 billion yuan, a year-on-year decline of 7.1% [4]. - Revenue changes for Q1 to Q3 2024 were 4.2%, -18.1%, and -7.1% respectively, indicating a narrowing decline in Q3 compared to Q2 [4]. Profitability Analysis - The gross profit margin in Q3 2024 increased by 1.3 percentage points, attributed to a higher share of medical terminal business [5]. - The net profit margin decreased by 5.9 percentage points to 1.9% year-on-year due to increased expenses [5]. Investment Outlook - The company is implementing comprehensive management reforms to enhance resource efficiency. The medical beauty business is expected to contribute more significantly to overall performance [5]. - EPS forecasts for 2024, 2025, and 2026 are 1.05, 1.53, and 1.87 yuan per share respectively [5].

证券代码：688363 证券简称：华熙生物 公告编号：2024-040 华熙生物科技股份有限公司 关于召开 2024 年第一次临时股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2024 年第一次临时股东大会 召开日期时间：2024 年 12 月 2 日 14 点 30 分 召开地点：北京市朝阳区建国门外大街甲六号华熙国际中心 D 座 36 层会议 室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2024 年 12 月 2 日 至 2024 年 12 月 2 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 股东大会召开日期：2024年12月2日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） 现场会议召 ...